Mediterranean Journal of Hematology and Infectious Diseases Outcome of Allogeneic Stem Cell Transplantation Conditioninig Regimen in Patients with Idiopathic Myelofibrosis: the G.i.t.m.o. Experience Intermediate or High Dupriez Score. Conditioning Regimens Were Based on Fludarabine plus Busulphan in

Background: Allogeneic stem cell transplantation (SCT) is a potentially curative treatment for myelofibrosis (MI), though limited by a high rate of transplant-related mortality (TRM). In the present study we evaluate the outcome of MI patients undergoing an allogenic SCT after reduced intensity conditioning (RIC) regimens, and the impact of prognostic factors. Design and methods: Fifty two patients were transplanted in 26 Italian centres between 1998 and 2006. We analyzed the influence of patient and disease clinical features before SCT and of transplant procedures on TRM and overall survival (OS) by means of univariate and multivariate analyses. Results: At SCT, median age was 52,5 years (32–68) and 89% of the patients had an intermediate or high Dupriez score. Conditioning regimens were based on fludarabine plus busulphan in 27% of patients, thiotepa plus cyclophosphamide in 46% and miscellaneous drug combinations in the other 27% of cases. Stem cells came from matched sibling donors for 75% of the patients and mismatched sibling or unrelated donors for the remaining 25%. The cumulative incidence of engraftment at day 90 after transplant was 83% (95% CI, 0.87–0.97). The estimated 1-year TRM was 30%. The estimated 3-year event-free-survival (EFS) and OS after hematopoietic SCT was 44% and 38% respectively. In multivariate analysis, an higher leukocyte count and circulating blasts in the peripheral blood before SCT significantly reduced EFS and OS respectively. Interpretation and conclusions: We conclude that the extension of the disease before transplantation based on the presence of circulating blasts and high leukocyte counts significantly affected the outcome after HSCT

[1]  G. Barosi,et al.  Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type , 2010, Bone Marrow Transplantation.

[2]  H. Einsele,et al.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.

[3]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[4]  R. Fanin,et al.  Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.

[5]  C. Pascutto,et al.  WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2008, Blood.

[6]  D. Dingli,et al.  Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. , 2007, Leukemia research.

[7]  R. Fanin,et al.  Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome , 2007, Leukemia.

[8]  F. M. Stewart,et al.  Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  N. Kröger,et al.  Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. , 2007, Blood.

[10]  A. Zander,et al.  Rapid Regression of Bone Marrow Fibrosis after Dose-Reduced Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. , 2006 .

[11]  L. Nilsson,et al.  Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens , 2006, British journal of haematology.

[12]  S. Forman,et al.  Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  R. Mesa,et al.  Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic , 2006, Cancer.

[14]  G. Barosi,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2006, Current opinion in hematology.

[15]  R. Hoffman,et al.  Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. , 2005, Blood.

[16]  J. Panse,et al.  Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis , 2005, British journal of haematology.

[17]  A. Elmaagacli,et al.  Outcome of allogeneic stem cell transplantation in patients with myelofibrosis , 2004, Bone Marrow Transplantation.

[18]  H. Deeg,et al.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis. , 2003, Blood.

[19]  W Hasegawa,et al.  Stem cell transplantation for myelofibrosis: a report from two Canadian centers , 2003, Bone Marrow Transplantation.

[20]  A. Verma,et al.  Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. , 2002, Blood.

[21]  H. Deeg,et al.  Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. , 2001, Blood.

[22]  H. Deeg,et al.  Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation , 2001, Leukemia.

[23]  F. Frassoni,et al.  Reduced intensity thiotepa–cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age , 2000, British journal of haematology.

[24]  A. Tefferi Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[25]  A. Nagler,et al.  The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. , 1999, Leukemia research.

[26]  H. Deeg,et al.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.

[27]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[28]  F. Benvenuto,et al.  Thiotepa Cyclophosphamide Followed by Granulocyte Colony-Stimulating Factor Mobilized Allogeneic Peripheral Blood Cells in Adults With Advanced Leukemia , 1996 .

[29]  F. Benvenuto,et al.  Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. , 1996, Blood.

[30]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[31]  B. Teicher,et al.  Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. , 1988, Journal of the National Cancer Institute.